Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 <1%, & High TMB? New Data from CheckMate 227 (BMIC-040)
